Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2013

01-08-2013 | Review Article

Calciphylaxis: diagnosis and clinical features

Author: Matsuhiko Hayashi

Published in: Clinical and Experimental Nephrology | Issue 4/2013

Login to get access

Abstract

Calciphylaxis is a relatively rare disease, observed mainly in patients on dialysis, associated with high mortality rates, and characterized by painful skin ulceration. The pathogenesis of calciphylaxis is virtually unknown, although several risk factors, including warfarin therapy, hypoalbuminemia, and disturbances in calcium–phosphate metabolism, have been reported. The prevalence of calciphylaxis in Japan is likely to be less than 1:10,000 dialysis patients per year based on our nationwide survey in 2009. However, the results of the survey also showed that about 60 % of nephrologists in Japan are not familiar with the disease itself and it is highly likely that calciphylaxis is being overlooked. To facilitate recognition of calciphylaxis, we have proposed diagnostic criteria. At present, there is no specific therapy for calciphylaxis and general supportive measures, especially antibiotics for the accompanying infection and wound care, are important. Recently, sodium thiosulfate has been increasingly used to treat calciphylaxis and its efficacy should be evaluated by large clinical trials.
Literature
1.
go back to reference Weenig RH. Pathogenesis of calciphylaxis. Hans Selye to nuclear factor κ-B. J Am Acad Dermatol. 2008;58:458–71.PubMedCrossRef Weenig RH. Pathogenesis of calciphylaxis. Hans Selye to nuclear factor κ-B. J Am Acad Dermatol. 2008;58:458–71.PubMedCrossRef
2.
go back to reference Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17:629–34.PubMedCrossRef Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17:629–34.PubMedCrossRef
3.
go back to reference Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science. 1961;134:1876–7.PubMedCrossRef Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science. 1961;134:1876–7.PubMedCrossRef
4.
go back to reference Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet. 1968;2(7563):323–5.PubMedCrossRef Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet. 1968;2(7563):323–5.PubMedCrossRef
6.
go back to reference Richardson JA, Herron G, Reitz R, Layzer R. Ischemic ulcerations of skin and necrosis of muscle in azotemic hyperparathyroidism. Ann Intern Med. 1969;71:129–38.PubMedCrossRef Richardson JA, Herron G, Reitz R, Layzer R. Ischemic ulcerations of skin and necrosis of muscle in azotemic hyperparathyroidism. Ann Intern Med. 1969;71:129–38.PubMedCrossRef
7.
go back to reference Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136:1273–80.PubMedCrossRef Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136:1273–80.PubMedCrossRef
8.
go back to reference Hayashi M,Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y, the Japanese Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transpl. 2012;27:1580–84. Hayashi M,Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y, the Japanese Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transpl. 2012;27:1580–84.
9.
go back to reference Hayashi M, Takamatsu I, Yoshida T, Kanno Y, Sato Y, Abe T, Hashimoto A, Hosoya T, Akiba T, Nakamoto H, Umezawa A, Shigematsu T, Fukagawa M, Kawamura T, Tanaka M, Sugino Y, The Japanese Calciphylaxis Group. Proposal of diagnostic criteria for calciphylaxis based on nationwide surveillance in Japan. J Jpn Soc Dial Ther. 2012;45:551–7 (English abstract). Hayashi M, Takamatsu I, Yoshida T, Kanno Y, Sato Y, Abe T, Hashimoto A, Hosoya T, Akiba T, Nakamoto H, Umezawa A, Shigematsu T, Fukagawa M, Kawamura T, Tanaka M, Sugino Y, The Japanese Calciphylaxis Group. Proposal of diagnostic criteria for calciphylaxis based on nationwide surveillance in Japan. J Jpn Soc Dial Ther. 2012;45:551–7 (English abstract).
12.
go back to reference Karpman E, Das S, Kurzrock EA. Penile calciphylaxis: analysis of risk factors and mortality. J. Urol. 2003;169(6):2206–9.PubMedCrossRef Karpman E, Das S, Kurzrock EA. Penile calciphylaxis: analysis of risk factors and mortality. J. Urol. 2003;169(6):2206–9.PubMedCrossRef
13.
go back to reference Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32:376–83.PubMedCrossRef Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32:376–83.PubMedCrossRef
14.
go back to reference Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324–32.PubMedCrossRef Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324–32.PubMedCrossRef
15.
go back to reference Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210–7.PubMedCrossRef Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210–7.PubMedCrossRef
16.
go back to reference Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56:569–79.PubMedCrossRef Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56:569–79.PubMedCrossRef
17.
go back to reference Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130:645–50.PubMedCrossRef Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130:645–50.PubMedCrossRef
18.
go back to reference Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35:588–97.PubMedCrossRef Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35:588–97.PubMedCrossRef
19.
go back to reference Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61(2):325–32.PubMedCrossRef Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61(2):325–32.PubMedCrossRef
20.
go back to reference Lal G, Nowell AG, Liao J, Sugg SL, Weigel RJ, Howe JR. Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery. 2009;146:1028–34.PubMedCrossRef Lal G, Nowell AG, Liao J, Sugg SL, Weigel RJ, Howe JR. Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery. 2009;146:1028–34.PubMedCrossRef
21.
go back to reference Vedvyas C, Winterfield LS, Vleugels RA. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol. 2012;67:e253–60.PubMedCrossRef Vedvyas C, Winterfield LS, Vleugels RA. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol. 2012;67:e253–60.PubMedCrossRef
22.
go back to reference Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15:172–86.PubMedCrossRef Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15:172–86.PubMedCrossRef
23.
go back to reference Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43:1104–8.PubMedCrossRef Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43:1104–8.PubMedCrossRef
24.
go back to reference Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009;5:539–43.PubMedCrossRef Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009;5:539–43.PubMedCrossRef
25.
go back to reference Sood AR, Wazny LD, Raymond CB, Leung K, Komenda P, Reslerova M, Verrelli M, Rigatto C, Sood MM. Sodium thiosulfate-based treatment in calcific uremic arteriolopathy: a consecutive case series. Clin Nephrol. 2011;75:8–15.PubMed Sood AR, Wazny LD, Raymond CB, Leung K, Komenda P, Reslerova M, Verrelli M, Rigatto C, Sood MM. Sodium thiosulfate-based treatment in calcific uremic arteriolopathy: a consecutive case series. Clin Nephrol. 2011;75:8–15.PubMed
26.
go back to reference Noureddine L, Landis M, Patel N, Moe SM. Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clin Nephrol. 2011;75:485–90.PubMed Noureddine L, Landis M, Patel N, Moe SM. Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clin Nephrol. 2011;75:485–90.PubMed
27.
go back to reference Kyriakopoulos G, Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail. 1990;12:213–9.PubMedCrossRef Kyriakopoulos G, Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail. 1990;12:213–9.PubMedCrossRef
Metadata
Title
Calciphylaxis: diagnosis and clinical features
Author
Matsuhiko Hayashi
Publication date
01-08-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0782-z

Other articles of this Issue 4/2013

Clinical and Experimental Nephrology 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.